Table 3.
Variable | Among Entire Cohort | |
---|---|---|
Multivariate | ||
OR (95% CI) | P Value | |
Age at diagnosis, y | ||
18–40 | 1[Reference] | |
41–60 | 0.59 (0.54–0.66) | < 0.001* |
61–80 | 0.46 (0.41–0.51) | < 0.001* |
> 80 | 0.46 (0.40–0.54) | < 0.001* |
Race | ||
White | 1[Reference] | |
Black | 1.54 (1.41–1.67) | < 0.001* |
Hispanic | 0.82 (0.74–0.91) | < 0.001* |
Asian or Pacific Islander | 0.81 (0.72–0.92) | 0.001* |
American Indian/Alaska Native | 0.93 (0.59–1.38) | 0.725 |
Unknown | 0.38 (0.19–0.68) | < 0.001* |
Marital status | ||
Unmarried a | 1[Reference] | |
Married | 0.64 (0.60–0.68) | < 0.001* |
Unknown | 0.83 (0.72–0.96) | 0.013* |
Insurance status | ||
Uninsured b | 1[Reference] | |
Insured | 0.53 (0.45–0.63) | < 0.001* |
Unknown | 0.48 (0.35–0.67) | < 0.001* |
Histology | ||
Infiltrating duct carcinoma | 1[Reference] | |
Lobular carcinoma | 0.68 (0.59–0.77) | < 0.001* |
Infiltrating duct and lobular carcinoma | 0.66 (0.55–0.79) | < 0.001* |
Other types c | 1.25 (1.14–1.37) | < 0.001* |
Pathological Grade | ||
I | 1[Reference] | |
II | 3.89 (3.28–4.65) | < 0.001* |
III/IV | 8.59 (7.26–10.23) | < 0.001* |
Unknown | 20.75 (17.32–25.02) | < 0.001* |
Extrahepatic metastatic sites to lung, brain and bone, No | ||
0 | 1[Reference] | |
1 | 58.49 (53.84–63.57) | < 0.001* |
2 | 123.15 (110.89–136.76) | < 0.001* |
All 3 | 246.17 (195.34–310.33) | < 0.001* |
Unknown | 299.10 (240.01–372.94) | < 0.001* |
Subtype | ||
HR+/HER2− | 1[Reference] | |
HR+/HER2+ | 3.13 (2.87–3.41) | < 0.001* |
HR−/HER2+ | 4.75 (4.30–5.25) | < 0.001* |
Triple-negative | 1.92 (1.73–2.12) | < 0.001* |
Unknown | 1.48 (1.31–1.68) | < 0.001* |
Notes: a including divorced, separated, single (never married), and widowed; b including insured, Insured/No specifics Any Medicaid; c including other histology of invasive breast cancer except Infiltrating duct carcinoma, Lobular carcinoma and Infiltrating duct and lobular carcinoma; + denotes positive; − denotes negative; * denotes a statistically significant P-value; HER2 Human epidermal growth factor receptor 2, HR Hormone receptor, OR Odds ratio, CI Confidence interval